MarginsXMarginsX
Home › Markets › Health Care › ADMA

ADMA Biologics Inc (ADMA)

ADMA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$13.47
-1.54% on the day
Market cap
$3.0B
Mid cap
Revenue · 2025
$510.2M
+19.6% on 2024
Net income · 2025
$146.9M
28.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/0001140361-26-006815-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerADMA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001368514
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$510.2M
Net income$146.9M
Operating income$191.4M
Net margin28.8%
Operating margin37.5%
Revenue growth+19.6%
Cash$87.6M
Total assets$624.2M
P/E (computed)20.3×
P/S (computed)5.9×

Warning signs

Cash runway
Cash-flow positive
$124.6M cash at September 30, 2026
Share count, 1 year
-6.8%
2025-11-03 to 2026-10-30 · -1.8% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$1.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$124.6M cash; operating cash flow $35.2M a quarter.Report 2026-09-30
Shares outstanding221,854,389 (2026-10-30); 237,997,765 a year earlier; 225,967,668 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Stamford, Connecticut, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $468K, sold $1.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$141.1M$49.9M$17.4M$124.6M$195.9M$519.2M10-Q 2026-11-04
Q2 2026
2026-06-30
$124.4M$37.8M$29.5M$136.0M$196.6M$512.3M10-Q 2026-08-05
Q1 2026
2026-03-31
$114.5M$45.3M$58.2M$138.2M$196.9M$509.9M10-Q 2026-05-06
Q4 2025
2025-12-31
$139.2M$49.4M$35.6M$87.6M$72.1M$510.2M10-K 2026-02-25
Q3 2025
2025-09-30
$134.2M$36.4M$13.3M$61.4M$72.4M$488.6M10-Q 2026-11-04
Q2 2025
2025-06-30
$122.0M$34.2M$21.1M$90.3MNo debt tags$474.2M10-Q 2026-08-05
Q1 2025
2025-03-31
$114.8M$26.9M-$19.7M$71.6MNo debt tags$459.4M10-Q 2026-05-06
Q4 2024
2024-12-31
$117.5M$111.9M$50.2M$103.1M$72.3M$426.5M10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52022-12-07
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-15

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+7.5%
1 month+32.7%
3 months+45.4%
Year to date-25.0%
1 year-12.9%
From 52-week high-32.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
VCELVericel Corporation$57.48+0.91%$2.9B
DNLIDenali Therapeutics Inc.$18.08-3.52%$2.9B
IOVAIovance Biotherapeutics Inc.$7.55-2.71%$3.5B
RLAYRelay Therapeutics Inc.$17.27-4.53%$3.8B
TARSTarsus Pharmaceuticals Inc.$78.68-1.99%$3.9B
CRSPCRISPR Therapeutics AG Common Shares$40.37-4.43%$3.9B
BEAMBeam Therapeutics Inc.$20.94-8.28%$2.2B
REPLReplimune Group Inc.$21.41-2.19%$2.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier